CDC advisers recommend Pfizer or Moderna's COVID-19 vaccine over Johnson & Johnson's due to rare blood clots
CBSN
A panel of the CDC's outside vaccine advisers voted unanimously Thursday to back recommendations preferring Pfizer and Moderna's COVID-19 vaccines over Johnson & Johnson's, in light of new data presented to the panel about the risk of a rare blood clotting side effect linked to the Johnson & Johnson shot.
Nine deaths linked to the clotting issue have been identified following receipt of the Johnson & Johnson vaccine, out of more than 16 million people first vaccinated with that single-shot vaccine in the United States. Seven of the deaths have been in women and two were in men.
The advisers said Johnson & Johnson's shots should be reserved for cases in which people could not receive, or did not want, the widely-available Pfizer and Moderna vaccines.
